Connect with us

Technology

ARMR Sciences Achieves Major Milestone Toward Overdose Protection, Produces First-Ever Anti-Fentanyl Immune Response in Humans

Published

on

Interim phase 1/2 data confirm significant anti-fentanyl antibody production at the lowest dose, with a well-tolerated safety profile across all patients dosed.

NEW YORK, June 17, 2026 /PRNewswire/ — ARMR Sciences, a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl, today announced that its lead product, ARMR-100, has generated an anti-fentanyl immune response against fentanyl in humans while showing favorable safety data. The result demonstrates that the formulation can produce an immune response in humans and marks a critical milestone in the company’s path toward demonstrating that this response can protect against fentanyl.

ARMR-100 is being designed to work with the body to generate a protective immune response. The product, in a Phase 1/2 clinical trial, is being developed to generate an immune response that produces anti-fentanyl antibodies capable of binding to lethal synthetic drugs. Once the antibodies bind to the synthetic drug target, such as fentanyl, the drug is prevented from entering the brain. If the molecule is prevented from reaching the brain, then the downstream effects that lead to overdose may also be prevented. ARMR-100 is in development to be the first long-lasting preventive medication against fentanyl, with the goal that the product endures for 6-12 months in healthy adults. The next phase is evaluating protection against fentanyl, currently on track to begin in Q3 2026.

“The antibody response we observed at the lowest dose level tested has been robust, with anti-fentanyl IgG titers well above pre-vaccination baseline. These early immunogenicity data are encouraging as we advance to higher dose cohorts and, ultimately, to the human fentanyl challenge phase of the study,” said Dr. Seth Toback, Chief Medical Officer of ARMR Sciences.

Fentanyl, a lethal killer, is responsible for approximately 100+ American deaths per day1. According to the latest CDC data, overdose has become the leading cause of death for Americans aged 18 to 45, driven primarily by fentanyl and other synthetic drugs2. Over the last 10 years, more than 450,000 lives have been lost to the drug3. This exceeds the total amount of U.S. combat deaths in WWII.

ARMR believes that the data represent a foundational milestone in its development program. Establishing that the vaccine can elicit an immune response in humans is the prerequisite for the company’s central thesis: that vaccine-induced antibodies can intercept fentanyl before it reaches the brain. With evidence of human immunogenicity now demonstrated, ARMR expects to advance to the next phase of its clinical trial, designed to evaluate the protective efficacy of this immune response against fentanyl, which is expected to begin in August.

“We are turning what many called impossible into reality,” said Collin Gage, CEO of ARMR Sciences. “These positive early results are a testament to the deeply experienced team of scientists, researchers, and medical professionals we have assembled. While there is still important work ahead, we believe today’s milestone further validates our approach and reinforces our confidence in the path forward as we continue advancing a potential solution that could save countless lives.”

ARMR-100 has been well tolerated across the first three patient cohorts, comprising 24 patients in total. Enrollment began in March 2026, and to date, three groups of eight participants have been dosed. The study Safety Committee has reviewed the data at multiple points and has authorized the trial to advance to higher dose levels.

No serious medical events have been observed. Reported adverse events have been minor, infrequent, and short-lived, consisting primarily of occasional headaches and consistent with the typical response to other inoculations. The safety profile observed to date supports the candidate’s continued advancement to higher-dose cohorts and the next phase of clinical evaluation.

ARMR-100 generated this immune response at the lowest dose of this escalation study, representing the floor of the program’s dosing range. Even at this dose, early participants have shown a meaningful increase in anti-fentanyl antibodies following vaccination, meeting the requirements to enter the planned fentanyl challenge phase of the study. Achieving a strong human immune response at the lowest dose is an encouraging signal as the company moves toward testing protective efficacy. The forthcoming phase will assess, in humans, the degree of protection conferred by this immune response against fentanyl.

“Seeing this immune response in human subjects demonstrates a critical translation of the seminal work by Professor Colin Haile and his team in the discovery of ARMR-100,” said Dr. Nick Jacob, chief scientific officer of ARMR Sciences.

In rodent models, ARMR-100 produced robust protection, preventing an estimated 90% to 100% of fentanyl from reaching the brain and eliminating its downstream behavioral effects that may lead to addiction. ARMR-100 has previously shown in preclinical research that it does not cross-react with critical pain medications currently used in emergency room settings and post-operative care. This selectivity means that important analgesic medications can still be used to manage pain in an emergency. Additionally, in preclinical models, ARMR-100 has been shown to work alongside currently available reactive overdose treatments, such as naloxone.

ARMR-100 employs a natural, protein-based, heavy metal-free formulation that does not contain aluminum, thimerosal, mercury, or other heavy metal-based additives. This formulation approach is a core feature of the candidate’s profile as the program advances.

About ARMR Sciences

ARMR Sciences is a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, including fentanyl, and other emerging chemical threats. The company’s lead product, ARMR-100, is designed to generate a protective immune response that produces antibodies capable of binding synthetic molecules and blocking them from reaching the brain.

For more information, visit https://armrsciences.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated timing and design of ARMR Sciences’ clinical trials, the potential of ARMR-100 to generate a protective immune response and to protect against fentanyl overdose, the targeted duration of that protective response, its selectivity relative to therapeutic pain medications, its compatibility with existing overdose rescue treatments, and the company’s development plans. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the conduct, timing, and results of clinical trials; the unpredictability of preclinical and clinical data; regulatory review and approval; and the company’s ability to obtain financing. Preclinical results, including the protection, selectivity, and compatibility observed in animal studies, are not necessarily predictive of results in humans. ARMR Sciences undertakes no obligation to update any forward-looking statement except as required by law.

https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htmhttps://www.dea.gov/press-releases/2024/01/31/year-review-dea-rocky-mountain-field-division-sees-record-year-fentanylhttps://www.nationalww2museum.org/students-teachers/student-resources/research-starters/research-starters-worldwide-deaths-world-war

Investor and Media Contact
Andy Dueñas
armr@capvstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/armr-sciences-achieves-major-milestone-toward-overdose-protection-produces-first-ever-anti-fentanyl-immune-response-in-humans-302802572.html

SOURCE ARMR Sciences Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Enghouse Announces Finance Leadership Change

Published

on

By

MARKHAM, ON, Aug. 26, 2026 /CNW/ — Enghouse Systems Limited (TSX: ENGH) today announced that Rob Medved, Chief Financial Officer, will be leaving the Company following the release of its third quarter financial results to pursue another professional opportunity.

Mr. Medved has been a valued member of the Enghouse leadership team. During his tenure of approximately 9 years, he has played a key role in supporting the Company’s financial discipline and strengthening Enghouse’s financial organization. The Board of Directors and Enghouse management team thank him for his dedication, professionalism and contributions to the Company. We appreciate the leadership and financial expertise he has brought to Enghouse and wish him every success in the next chapter of his career.

In connection with this transition, the Company is pleased to announce that Vinh Lien will be promoted to Vice President, Finance, effective upon Mr. Medved’s departure. Mrs. Lien has been with Enghouse for over ten years and has held several progressively senior finance and accounting roles during her tenure with the Company. In her current role as Corporate Controller, she has been responsible for overseeing global financial and accounting operations.

Mrs. Lien has been an integral member of the Enghouse Global Finance and accounting team with a deep understanding of Enghouse’s financial operations. She has consistently demonstrated strong leadership, sound judgment, and a thorough understanding of the Enghouse business. Her experience and commitment to both financial and operational excellence make her well qualified to assume this role.

The Company expects a seamless transition of responsibilities and does not anticipate any disruption to its operations, financial reporting, or strategic initiatives.

About Enghouse Systems Limited
Enghouse Systems Limited is a Canadian publicly traded company (TSX: ENGH) that provides enterprise software solutions focused on contact centers, video communications, virtual healthcare, telecommunications networks, public safety, and transportation markets. Enghouse employs an acquisition-oriented strategy and operates globally through a network of international subsidiaries.

SOURCE Enghouse Systems Limited

Continue Reading

Technology

INTOUCH INSIGHT ANNOUNCES Q2 2026 FINANCIAL RESULTS

Published

on

By

OTTAWA, ON, Aug. 26, 2026 /CNW/ — Intouch Insight Ltd. (TSXV: INX) (OTCQX: INXSF) (“Intouch” or the “Company”), a provider of customer experience measurement solutions, today announced its financial results for the second quarter ended June 30, 2026.

Financial Highlights

Highlights from the three months ended June 30, 2026, compared to the same period in 2025:

Revenue is 8% higher than the prior year. This increase was due to organic growth in SaaS, merchandising and recurring services revenue.Gross margin as a percentage of revenue was 46.7%, compared to 50.4% in the comparative period. This decrease is due to the mix of product sales, coupled with growth of some of our most competitively priced programs.Earnings from operations were $54,361 compared to a loss of $1,021,120 for Q2 2025. The loss in the prior year is due to the impairment of goodwill and intangibles from the loss of a client obtained through acquisition.SaaS revenue increased 18% to $474,999, recurring services revenue increased 6% to $5,879,676, and event marketing automation revenue increased 8% to $572,560.Merchandising revenue was $82,824, compared to nil in the prior year period.Net loss was $43,136, or $0.00 per share basic and diluted, compared to a net loss of $1,112,023, or $0.04 per share basic and diluted, in Q2 2025.Adjusted EBITDA, a non-IFRS measure, was $227,559 compared to $370,812 in Q2 2025; a reconciliation to the most directly comparable IFRS measure is contained in the Company’s MD&A for the period, which is available on SEDAR+ and is incorporated by reference.

Adjusted EBITDA is a non-IFRS financial measure, which is defined as net earnings (loss) before income taxes, adjusted to exclude finance costs, depreciation and amortization, impairment charges, share-based compensation, investment tax credits, and the change in the fair value of contingent consideration.

Highlights from the six months ended June 30, 2026, compared to the same period in 2025:

Revenue is 7% higher than the prior year. This increase was due to growth in SaaS, merchandising and recurring services revenue.Gross margin as a percentage of revenue was 48.1%, compared to 50.4% in the comparative period. This decrease is due to the product mix.Earnings from operations were $237,896 compared to a loss of $649,769 for 2025. The loss in the prior year is due to the impairment of goodwill and intangibles.Merchandising revenue was $120,291, compared to nil in the prior year period.Net income was $64,169, or $0.00 per share basic and diluted, compared to a net loss of $899,421, or $0.04 per share basic and diluted, in the first half of 2025.

Recent Operational Highlights

Presented the Company’s annual convenience industry study during the main stage general session at the Outlook Leadership Conference, hosted by Informa, and announced the top-performing convenience operator award in partnership with CSP Daily News. This year’s study encompassed close to 3,000 site visits across 14 leading convenience brands.Advanced the Company’s entry into the grocery vertical, including proprietary grocery research produced in partnership with Informa Connect and NexChapter, which the Company presented during the general session at the GroceryNEXT conference in Chicago on August 24-26, 2026.Published two proprietary thought leadership studies, the 2026 Emerging Experiences Study on mobile order ahead and the 2026 C-store Trends Report, both of which heighten the Company’s industry profile.Advanced through the qualification stages of a previously disclosed seven-figure SaaS RFP within the Company’s core QSR vertical and is one of the remaining finalists.Secured a second merchandising customer and added contracted merchandising work that is expected to support a significant sequential increase in merchandising revenue in the third quarter of 2026.

Management Commentary

Cameron Watt, President & Chief Executive Officer of Intouch Insight, commented:

“The second quarter delivered exactly what we said it would. Revenue grew 8% to $7,015,784, our strongest quarterly growth rate in seven quarters, with growth across each of our major product lines, and we did it while continuing to fund the investments that we committed to at the start of the year. We told the market we would invest into growth without diluting shareholders, and we have not issued a single share to do it. We intend to fund these investments from cash generated by operations and our existing credit facilities, and we do not anticipate that an equity financing will be required.”

Watt added:

“Our goal to double the business by the end of 2028 remains our focus and our 2026 expectations are unchanged: double-digit organic revenue growth by year end, more than $1 million of merchandising revenue, and continued investment in our strategy, which may result in an operating loss. Merchandising has been slower off the line than we wanted, but the shape of the year is intact. Based on contracts signed to date, we expect third quarter merchandising revenue on its own to exceed the combined revenue of the first half.  We are continuing to pursue our stated strategy and remain optimistic in achieving our goals.”

Q2 Earnings Conference Call Information

To participate in this event, register and log-in approximately 5 to 10 minutes before the beginning of the call.

Date: August 27, 2026 
Time: 10:30 a.m. eastern time

Register for the live webcast and access on-demand recording: click here. https://events.zoom.us/ev/ApEXp4MTIT3r7mdIyMnepiOj0JWWQZz-8QK_9Gn0AtLGAC-R-pYn~Anj41TOs5ON_y0VBbXslnvdVEyaq_Dsmqwga9gdn5FSs1jbXHdNT1B07Hw  

Consolidated Statements of Operations

Q2 2026

Q2 2025

Revenue

$   7,015,784

$   6,503,539

Cost of services

3,740,310

3,225,447

Gross margin

3,275,474

3,278,092

Total operating expenses

3,221,113

4,299,212

Income from operating activities

54,361

(1,021,120)

Non-operating (expenses) income 

(97,284)

(82,423)

Income tax recovery (expense)

(213)

(8,480)

Net income (loss)

$       (43,136)

$  (1,112,023)

About Intouch Insight

Intouch Insight offers a complete portfolio of customer experience management (CEM) products and services that help global brands delight their customers, strengthen brand reputation and improve financial performance. Intouch helps clients collect and centralize data from multiple customer touch points, gives them actionable, real-time insights, and provides them with the tools to continuously improve customer experience. Founded in 1992, Intouch is trusted by over 300 of North America’s most-loved brands for their customer experience management, customer survey, mystery shopping, mobile forms, operational and compliance audits, geolocation data capture and event marketing automation solutions. For more information, visit intouchinsight.com.

Certain statements included in this news release including those related to the Company’s quarterly results, future products, opportunities and cost initiatives, strategies, and other statements that are predictive in nature that depend upon or refer to future events or conditions, or that include words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, or similar expressions, are forward-looking statements within the meaning of applicable Canadian securities laws.  Forward looking statements that are made as of the date hereof, which by their nature are necessarily subject to risks and uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such statements reflect the Company’s current views with respect to future events, and are based on information currently available to the Company and on hypotheses which it considers to be reasonable; however, management cautions the reader that hypotheses relative to future events which are beyond the control of management could prove to be false, given that they are subject to certain risks and uncertainties. Please refer to the risks set forth in the Company’s most recent annual MD&A and the Company’s continuous disclosure documents that can be found on SEDAR+ at www.sedarplus.ca. The Company does not intend, and disclaims any obligation, except as required by law, to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Intouch Insight Ltd.

Continue Reading

Technology

Voltage Energy Will Seek New Trial and Review of Verdict in Shoals Patent Dispute

Published

on

By

CHAPEL HILL, N.C., Aug. 26, 2026 /PRNewswire/ — Voltage Energy Group (“Voltage Energy”), a leading solar and clean energy solutions provider founded in North Carolina, today confirmed that it will seek a new trial following the jury’s verdict in Voltage’s ongoing patent dispute with Shoals Technologies Group, Inc. (“Shoals”) in the Middle District of North Carolina.

Voltage Energy strongly disagrees with the jury’s verdict and believes the judgment is not supported by legally sufficient evidence or the law. The Company will pursue all available post-trial remedies.

“We are confident in our record for appeal and the Court’s prior findings that Shoals violated an agreement prohibiting its counsel’s involvement in obtaining these patents,” said Li Wang, CEO of Voltage Energy. “Voltage independently developed LYNX in 2021 through its own engineering efforts, three years before the patents asserted by Shoals were issued. Our focus remains on proudly powering the renewable energy industry.”

LYNX PLUS, the Company’s latest trunk bus solution featuring a 2kV architecture, 0.5–0.8% higher yield, 10–15% material savings, and 34% voltage-drop reduction, remains in full production and continues to ship to customers as scheduled. Building on this foundation, Voltage Energy will proudly unveil new products and technologies at RE+ 2026, taking place November 17–19 at the Las Vegas Convention Center. Customers and partners are invited to explore its latest solutions at Booths N936 and N736. The upcoming opening of Power Ranch in Roxboro, North Carolina, will further mark the Company’s next milestone in expansion and innovation roadmap.

About Voltage Energy Group

Founded in 2016, Voltage Energy Group (“Voltage Energy”) is a leading global provider of mission-critical power architecture solutions for utility-scale solar, BESS, and data center segments. Headquartered in Chapel Hill, North Carolina, Voltage Energy operates globally with offices in Frankfurt, Germany; Sydney, Australia; and Abu Dhabi, United Arab Emirates.

Rooted in utility-scale solar EBOS, Voltage Energy delivers safe, reliable, and scalable infrastructure solutions that power our partners to move forward with confidence. We strengthen our core business today while building the capabilities required to meet tomorrow’s mission-critical energy and infrastructure needs, from BESS and data centers to microgrids and beyond.

Learn more about us at www.voltageenergy.com.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/voltage-energy-will-seek-new-trial-and-review-of-verdict-in-shoals-patent-dispute-302861020.html

SOURCE Voltage Energy Group

Continue Reading

Trending